Renaissance Technologies LLC trimmed its position in Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) by 63.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,600 shares of the company’s stock after selling 36,305 shares during the quarter. Renaissance Technologies LLC owned about 0.07% of Candel Therapeutics worth $128,000 at the end of the most recent reporting period.
Separately, Rhumbline Advisers purchased a new position in shares of Candel Therapeutics in the 2nd quarter worth approximately $143,000. 13.93% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Candel Therapeutics
In related news, insider Charles Schoch sold 9,884 shares of the company’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $6.47, for a total transaction of $63,949.48. Following the completion of the sale, the insider now directly owns 62,520 shares in the company, valued at $404,504.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Candel Therapeutics news, insider Charles Schoch sold 9,884 shares of the stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $6.47, for a total value of $63,949.48. Following the completion of the sale, the insider now directly owns 62,520 shares in the company, valued at approximately $404,504.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CTO Seshu Tyagarajan sold 14,851 shares of Candel Therapeutics stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $6.47, for a total transaction of $96,085.97. Following the completion of the sale, the chief technology officer now owns 146,049 shares of the company’s stock, valued at $944,937.03. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 49,063 shares of company stock valued at $318,122. Company insiders own 41.60% of the company’s stock.
Candel Therapeutics Trading Up 0.2 %
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.74) earnings per share for the quarter. As a group, analysts anticipate that Candel Therapeutics, Inc. will post -0.91 earnings per share for the current year.
About Candel Therapeutics
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Further Reading
- Five stocks we like better than Candel Therapeutics
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- Using the MarketBeat Dividend Tax Calculator
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- Insider Trades May Not Tell You What You Think
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Want to see what other hedge funds are holding CADL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report).
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.